Over the last four decades, studies have shown that the phenotype associated with NPPA genetic variants and the changes in the circulating levels of ANP reflect its value as a potential therapeutic target for cardiometabolic diseases, including heart failure [70, 71]. This evidence concerns the gene NPPA and heart failure.